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Abstract
Estimating the age-specific incidence of an emerging pathogen is essential for understanding its severity and transmission
dynamics. This paper describes a statistical method that uses likelihoods to estimate incidence from sequential serological
data. The method requires information on seroconversion intervals and allows integration of information on the temporal
distribution of cases from clinical surveillance. Among a family of candidate incidences, a likelihood function is derived by
reconstructing the change in seroprevalence from seroconversion following infection and comparing it with the observed
sequence of positivity among the samples. This method is applied to derive the cumulative and weekly incidence of A/H1N1
pandemic influenza in England during the second wave using sera taken between September 2009 and February 2010 in
four age groups (1–4, 5–14, 15–24, 25–44 years). The highest cumulative incidence was in 5–14 year olds (59%, 95% credible
interval (CI): 52%, 68%) followed by 1–4 year olds (49%, 95% CI: 38%, 61%), rates 20 and 40 times higher respectively than
estimated from clinical surveillance. The method provides a more accurate and continuous measure of incidence than
achieved by comparing prevalence in samples grouped by time period.
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Introduction
Rapid understanding of the severity profile and transmission
dynamics of an emerging pathogen is essential in order to
anticipate demands on health care resources and develop
appropriate public health interventions. While cases reported
through clinical surveillance systems, such as statutory notifications
or sentinel physician reporting schemes, may reflect the time
course of the wave of infection, they may not provide an accurate
measure of the infection rate in the population. For A/H1N1
(2009), the occurrence of asymptomatic infections or clinical cases
for which no medical care is sought can lead to gross
underestimation of the true incidence of infection [1,2] and
overestimation of severity [3], when using clinical surveillance
data.
We previously reported the results of a rapid serosurvey that
provided early estimates of the age-specific incidence of infection
with the A/H1N1 (2009) virus during the first wave in England
[2]. For this, age-specific incidence estimates were derived by
testing sequential serum samples grouped by calendar month and
comparing the prevalence of antibody to the H1N1 (2009)
influenza virus in that month with that in the same age-group in
baseline samples collected prior to its arrival in the United
Kingdom. This method has a number of limitations. First, the
monthly samples are distributed over a 30 day period during
which incidence may be changing, particularly at the height of the
wave. Second, the variable time to seroconversion across
individuals means that even if all samples were taken on the same
date they reflect incidence at different times in the previous weeks.
Third, derivation of incidence by comparing prevalence between
time points reduces the precision of the estimate for a given sample
size and may result in negative point estimates for groups in whom
incidence is low [2], unless a method is used that prohibits such
estimates.
We report the age-specific incidence of infection in the second
wave in England using a novel statistical method for analyzing
sequential serology data. In this example, we utilize information
on the temporal distribution of cases as estimated from clinical
surveillance data combined with information on seroconversion
interval and the exact timing of each serum sample to estimate
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17074incidence by week. Our method provides a better definition of the
age-specific incidence of an emerging pathogen over time-
information that is critical for the parameterization and validation
of predictive models and for assessing disease severity.
Materials and Methods
Serologic data
Serum samples were residual aliquots obtained from chemical
pathology and microbiology laboratories in eight regions in
England and sent to the Manchester Seroepidemiology Unit
(SEU), after being irreversibly unlinked from any patient
identifying information according to the standard SEU protocol
[4]. Due to limitations on the numbers of samples that could be
tested each month, continuous collection of sera throughout the
second wave was only carried out for those aged under 45 years
[5]. The analysis was therefore restricted to 2684 samples from
individuals aged 1 to 44 years taken from 1
st September 2009 to
23
rd February 2010. The information available for each sample
was date of collection, age, sex and collecting laboratory. Sera
were tested for antibody to H1N1 (2009) influenza virus by
haemagglutination inhibition (HI) using standard methods as
previously described [2,5] at the Respiratory Virus Unit at the
Centre for Infections Health Protection Agency, United Kingdom.
The starting dilution for the HI assay was 1:8 and sera were
titrated by doubling dilution to determine absolute end point titers
ending at a dilution of 1:16384. As used previously [2], the
threshold titre for positivity used in the analysis was $32, four
times the minimum level of detection. Comparison of the HI titer
distribution in pre-pandemic and post- pandemic sera from
children under 15 years of age showed this threshold to be a
highly specific marker of recent infection [5].
Ethical review
Approval for the unlinked anonymous testing of sera from the
SEU collection was obtained from the National Research Ethics
Service (NRES reference number 05/Q0505/45).
Time course of the second wave
Information on the distribution of clinical cases of H1N1 (2009)
by age group and week in England between August 2009 and
February 2010 was obtained from the weekly estimates of the
number of clinical cases made by the Health Protection Agency
(HPA) during the course of the pandemic, as previously described
[6]. Briefly, these estimates used health care consultation rates by
age for influenza-like-illness (ILI) adjusted for the estimated
proportion of patients with ILI seeking health care, and the
proportion consulting in whom H1N1 (2009) infection was
laboratory-confirmed by a validated PCR assay [7].
Distribution of seroconversion interval
For estimation of the distribution of seroconversion intervals
(here defined as the time taken to reach an HI titer of $32) in days
since symptom onset, serum samples from named patients with
suspected pandemic influenza sent to the Respiratory Virus Unit
by clinicians for HI antibody testing as part of their clinical work
up were cross checked against the database of individuals with
PCR confirmed infection held by the Respiratory Virus Unit. This
provided a data set of individuals with serum samples taken at
various intervals after onset of a confirmed infection. The date of
onset of symptoms was obtained by follow up via the patient’s
general practitioner if not supplied with the serum sample or
available via the national database established by the HPA early in
the pandemic to facilitate tracking of confirmed cases. This linkage
yielded 115 HI titers from patients with known dates of sample
and symptom onset for analysis.
Not all infected individuals attain a titer of $32 by HI [2,5]. We
assume that the distribution A(t) of the seroconversion interval t,
following infection, is given by a mixture distribution where Sfinal
is the probability of ever seroconverting conditional on infection,
and conditional on seroconversion, the time from infection to
seroconversion is Weibull. We thus need to evaluate three
parameters to evaluate the interval to seroconversion distribution,
Sfinal and the two parameters from the Weibull distribution.
Parameters for the Weibull function describing the time from
infection to seroconversion were sampled using Markov Chain
Monte Carlo (MCMC) and a simple Metropolis-Hasting algo-
rithm with uniform priors for the three parameters. To assess
convergence, several chains with different starting values were run
in parallel. Iterations were stopped when enough samples were
generated to see agreement between the estimates from the
different chains [8]. We assumed that seroconversion interval and
proportion seroconverting did not differ by age group [5].
Derivation of the incidence
We start, for an age group i, with a family of possible incidence
curves Ik
i (t) parameterized by k. The aim of the method is to assess
from the sequence of serologic samples which incidence curves are
the most likely to have generated the observed sequence of
seropositivity in the samples by working out their posterior
distribution. We assume in this paper that the incidence is
constructed from the proportion of cases by week over time based
on the normalized HPA clinical case estimates multiplied by an
unknown cumulative incidence. We thus restrict the estimation of
the incidence curves for the different age groups to one parameter,
the cumulative incidence i.e. the final proportion in the age group
that was infected during the second wave. The final result of the
calculation is then a posterior distribution of cumulative incidences
based on a likelihood function given by the sequence of positivity
observed in the samples and a prior distribution for the cumulative
incidences. We assume these priors to be uniform over [0,1].
To estimate when the people developing symptoms will
achieve an HI titer of $32), the distribution A(t) of intervals
from onset of symptoms to seroconversion is needed. Knowing
this distribution, the number of people who seroconvert at time s
after onset of symptoms (or at an equivalent time after exposure if
they are asymptomatic) is given by
Ð s
0 Ik
i (s{u)A(u)du; summing
all the people who had onset of symptoms at time s-u weighted by
the proportion of them who seroconvert in an interval of time u.
This assumes that all people who seroconvert through infection
are initially seronegative (HI titer ,32). The change of
seroprevalence pk
i (t) of antibody in age group i is then given by
summing over the course of the epidemic (starting at t=0) all the
individuals who seroconverted and adding them to the pre-
epidemic baseline p0
i :
pk
i (t)~
ðt
0
ðs
0
Ik
i (s{u)A(u)dudszp0
i ð1Þ
Then, assuming that samples are drawn at random from the
population for whom we wish to derive incidence, i.e. the
population of England, and that there is no spatial heterogeneity,
the probability of having a positive sample at time t is given by
pk
i (t).
Assuming independence of the samples, the likelihood of
observing the data D given the incidence Ik
i is given by:
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with Jz denoting the set of positive samples, J{ the set of
negative samples and tj the time of collection of sample j. Following
Bayes’ theorem, the probability of incidence Ik
i given the observed
data is proportional to L(Djk,i) times the prior probability of the
incidence (we assume 0-1 uniform priors for the rest of the study).
Algorithm to compute incidences incorporating
uncertainty
To draw a sample from the posterior distribution of the
cumulative incidences (in each age group, so i is fixed) while taking
into account the uncertainty from the interval to seroconversion,
we used a rejection sampling algorithm. The algorithm will lead to
the correct distribution as soon as the acceptance rate is
proportional to the likelihood function [9]. We thus employed
the following algorithm:
1. Generate a sample H~fh1,:::,hNg of distributions of the
parameters for the interval to seroconversion distribution using
MCMC.
2. Draw a value from H and from the prior of the cumulative
incidence (uniform over [0,1])
3. Accept the sample with a probability
L(Djk,i)
M
, with M a
constant such that Mwmax(L(Djk,i))
4. Repeat until the required number of samples is achieved.
Given that the evaluation of our likelihood function only
depends on one parameter, it is straightforward to find a constant
M such that Mwmax(L(Djk,i)). For this, we have computed the
likelihood for a grid of values of cumulative incidences and
samples of H and have taken M as twice the maximum value
found. The bigger the value of M, the lower the probability of
acceptance will be, but the smaller the value of M the bigger the
risk of numerical inaccuracies. The value of the likelihood function
has been checked during the analysis to be below the chosen value
of M. More sophisticated approaches could be taken to choose a
more optimal value of M though the value chosen demonstrated
computational efficiency for our purpose.
We apply this method to find the cumulative incidence in the
age-groups 1–4, 5–14, 15–24 and 25–44 years during the second
wave of H1N1 (2009) in England using the distribution of cases by
week from clinical surveillance data to describe the temporal
variation of the incidence. The seroprevalence is reconstructed by
integrating Equation 1, with a time step of one day, the weekly
cases being spread uniformly over the week. The candidate final
cumulative incidences are assigned a likelihood function depend-
ing on the sequence of positivity of the samples in each age group
by using Equation 2. As the prior distributions of the cumulative
incidences are uniform over [0,1], to find the posterior distribution
of the incidences, the likelihood function is renormalized so that it
sums to one. The baseline seroprevalence was defined as the
proportion positive among the 1272 samples taken during the last
two weeks of the first wave and the first two weeks of the second
wave (August 17
th to September 13
th 2009).There were significant
differences in prevalence of antibody to H1N1(2009) virus between
regions in the samples collected in September and October 2009
(consistent with the different attack rates between regions in the
first wave [2]). However, these regional differences were
considerably reduced by February 2010 [5] and for this
methodological example data have been combined across regions
for all time points.
Estimation of total number of infections and comparison with
estimates derived from clinical surveillance.
For estimation of the total number of infections by age in the
second wave, the final cumulative incidence was multiplied by the
number of individuals in that age group in England, as obtained
from the Office of National Statistics Mid 2008 population [10].
These numbers were then compared with the cumulative number
of clinical cases in each age group as estimated by the HPA during
the second wave [6].
Results
The distribution of clinical cases in the second wave by week
was similar in the four age groups, though with an earlier peak in
the 5–14 and 15–24 year olds (Figure 1). The drop in clinical
incidence in the 5–14 year olds in November coincided with
school closure for half term.
Distribution of time to seroconversion
The posterior mean values for the scaled Weibull distribution
parameters are Sfinal =0.87 [0.77, 0.94], shape=2.42 [1.44,
4.26] and scale=12.87 [9.55, 16.98]. This means that, among
those who do seroconvert (87%), 50% will have seroconverted
by the 12
th day and 95% by the 21
st day (Figure 2). The
posterior covariance matrix for the parameters (Sfinal, shape and
scale) is:
1:9e{3 {5e{32 :8e{2
{5e{30 :55 {0:51
2:8e{2 {0:51 3:66
0
B @
1
C A:
Estimated cumulative incidence in the second wave
Posterior distributions for the estimated cumulative incidence
are shown in Figure 3 for the four age groups in the analysis. The
accuracy of the estimate depends on the number of samples. Even
in the 1–4 year age group where there is a limited number of
samples (n=274 over a 6 month period, Table 1), the distribution
is relatively well localized. The estimated cumulative incidence is
highest among 5–14 year olds with around 59% of individuals in
this age group, representing some 3.5 million children, likely to
have been infected in England in the second wave (Table 1).
Children aged 1 to 4 years have the second highest cumulative
incidence (49%) with 1.21 million likely infections. In the older age
groups, cumulative incidence is still high (35% and 25% in the 15–
24 and 25–44 year age groups respectively resulting in an
estimated 2.4 and 3.7 million infections respectively. When
compared with the number of clinical cases estimated by the
HPA method in the second wave [6], the estimated number of
infections were between 43 and 21 fold higher depending on the
age group (Table 1).
Change in seroprevalence and seroincidence during the
second wave
For each age-group, the observed proportions (with 95% CI) of
samples with HI titers $32 when grouped by week are shown in
Figures 4a–d. Also shown is the estimated cumulative seroprev-
alence and estimated cumulative seroincidence by day, each
starting from the baseline at the beginning of the second wave. In
contrast to the observed weekly seroprevalences, the estimated
cumulative seroprevalence increases monotonically.
Estimating H1N1 Pandemic Influenza Seroincidence
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A key element of the contingency planning for an influenza
pandemic in the United Kingdom has been the development and
validation of real time transmission models that can predict the
future impact on health care resources and evaluate the optimal
deployment of interventions such as school closure and vaccina-
tion [1,11,12]. Accurate and timely measures of the age-specific
incidence of infection as the pandemic evolves are essential for
model development and parameterization and are ideally obtained
from sequential serologic surveys. Estimates of the number of
infections are also essential for assessing severity as fatality and
hospitalization rates may be overestimated if denominators are
based on cases accessing health care [3,13]. The method described
here facilitates the generation of incidence data by the novel
application of a likelihood-based estimation to the analysis of
sequential serologic data. A similar likelihood approach has been
used recently for the estimation of the final attack rates but without
using surveillance data to obtain a continuous incidence curve
necessary for example to do modeling in real time [14].
Figure 2. Estimation of the interval to seroconversion. a) Proportion of individuals with HI titer ,32 by interval since symptom onset: blue
lines and points show the proportion in four-day intervals with confidence intervals and the red curve show the fitted parametric inverse cumulative
distributions with the 95% CI (credible intervals) and b) distribution of the time to seroconversion since symptoms with 95% CI.
doi:10.1371/journal.pone.0017074.g002
Figure 1. Proportion of clinial cases by week. Proportion of clinical cases by week for the second wave for four age-groups (1–4, 5–14, 15–24,
25–44 years) derived from clinical surveillance data.
doi:10.1371/journal.pone.0017074.g001
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an antibody assay that is a sensitive and specific marker of the
immune response to recent infection. The HI test developed by the
HPA had high specificity [5] and as no other influenza viruses were
circulating during the second wave in England the issue of the
development of cross reactive antibodies,which may occur with
exposure to antigenically-related influenza viruses, did not arise. The
HPA HI test has been extensively used to measure antibodies induced
by H1N1 (2009) vaccines [15,16] and detected antibodies at a titer of
$32 in 88% of individuals with confirmed infection tested more than
21 days after symptom onset. Some of the samples with a low HI titer
had antibodies to the H1N1 (2009) virus detected by micro-
neutralization assay, consistent with an immune response to recent
infection. The micro-neutralization is a more sensitive assay than HI
as it measures antibodies to other neutralizing epitopes in addition to
the haemagglutinin antigen. However, it is a more time consuming
assaytoperformandwouldnotbesuitablefortherapidgenerationof
serologic data for estimation of sero-incidence.
We assumed that HI antibodies developed in response to
infection remain at a titer of $32 for at least 7 months such that
individuals infected in August 2009 would still be seropositive if
tested in February 2010. Given that this threshold is a correlate of
Figure 3. Posterior distribution of the cumulated incidences. Estimated cumulated incidence distributions for age-groups 1–4, 5–14, 15–24,
25–44 years during the second wave.
doi:10.1371/journal.pone.0017074.g003
Table 1. Baseline percentage of samples with HI titer $32 before the start of the second wave, number of samples tested and
estimated cumulative incidence (with 95% credible intervals) over the second wave of H1N1 (2009) infection in England starting
from September 1
st 2009 according to age group.
Age group and number
of samples (n) tested
September 2009 to
February 2010
Prevalence
of HI
titers$32
before the
2
nd wave
Estimated cumulative
incidence over the 2
nd
wave
Population
size (2008) in
thousands
Estimated infections in
thousands from serology
Estimated clinical
cases in thousands
from surveillance
data **
Number of
infections per
estimated clinical
case
mean 95% CI* mean 95% CI
1–4 years, n=274 9.8% 49 38, 61 2,462 1,210 935; 1,510 28 43
5–14 years, n=840 14% 59 52, 68 5,904 3,500 3,080; 4,030 170 21
15–24 years, n=604 15.3% 35 28, 43 6,862 2,430 1,950; 2,980 102 24
25–44 years, n=966 12.3% 25 20, 31 14,417 3,670 2,930; 4,510 133 28
*CI, credible intervals,
**as described in reference 6.
doi:10.1371/journal.pone.0017074.t001
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maintained at this level in individuals with naturally-acquired
immunity. Generation of data on the kinetics of decay of HI
antibodies would ideally require sequential samples from a cohort
with known date of infection and followed up for antibody
persistence. In our seroconversion data set there was no evidence
of a decline in titers with time since onset after the seroconversion
peak at 10 days though we had few individuals with samples taken
.3 months after infection. However, if our method was applied to
estimate cumulative incidence over a more extended period, for
example from a baseline at the start of the first wave in April 2009,
and if titers were shown to decline below the HI threshold within
this time, a sero-reversion factor could be incorporated using the
knowledge of the kinetics of the antibody decay curve.
In applying the method to the serologic data from the second
wave, we assumed the incidence to be zero at baseline and that the
baseline prevalence was accurately known. The likelihood
estimation method though can still be applied if the baseline
seroprevalence at the start of a pandemic wave is unknown.
Providing that there are sufficient samples taken through the
course of the pandemic, the baseline could be estimated as part of
the parameter estimation. In this instance, the likelihood function
measures the chance of observing the data given the incidence
curve derived from clinical surveillance data, starting from the
candidate pandemic baseline. By adding a new quantity to
estimate the uncertainty will be increased on the other parameters
estimated (e.g. the total incidence) though this might reduce the
overall error.
Our method removes the possible negative changes in incidence
due to sampling variability when the number of sera tested and
change of seroprevalence between two months are small. Its
accuracy as a population measure will however depend on the
Figure 4. Changes in seroprevalence and cumulative incidence over time. Estimated changes in seroprevalence and cumulative incidence
compared with proportion with HI titer $32 by week by age group a) 1–4 years, b) 5–14 years c) 15–24 years d) 25–44 years.
doi:10.1371/journal.pone.0017074.g004
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that are obtained by random population sampling should be used
rather than sera obtained from individuals bled for other purposes.
However, use of residual aliquots of opportunistically available
samples seems a good proxy in the case of an emerging infection
such as pandemic influenza where there are high population attack
rates that are largely age-dependent. More relevant is whether the
change in the proportion with positive titers only reflects
acquisition of antibody from infection. In the United Kingdom,
vaccination with the A/H1N1 (2009) strain began in late
November 2009 for individuals in clinical risk groups in whom
the consequences of infection were shown to be more severe [17],
and from January 2010 was recommended for all children under 5
years of age [18]. However, the impact of vaccination in our data
set is likely to be small due to the low uptake rates [5] and has not
been taken into account in this methodological paper. Another
group where changes in seroprevalence may not reflect their own
infection are young infants in whom the detection of H1N1
antibody in the first few months of life may result from pre-natal
acquisition of maternal antibody rather than post-natal infection.
For this reason we excluded infants under 1 year of age from our
incidence analyses.
In addition to factors such as vaccination or antibody decay
which may influence the change in seroprevalence, there are likely
to be factors such as changes over time in the propensity to consult
or changes in proportion of patients tested for infection as the
pandemic evolves that will influence the shape of the incidence
curve derived from clinical or laboratory-based surveillance data.
Theoretically the shape of the incidence curve does not need to be
defined though in practice this might be difficult to implement
because of the large increase in parameter space needed to
describe the numerous putative incidences. Incorporating such
additional factors would require a more complex set of parameters
to be estimated in order to derive sero-incidence. For this MCMC
could be used with the likelihood function from Equation 2 to
draw a sample from the parameter space and then the parameters
can be evaluated from the sampled distribution.
Due to the necessary lag times in sample collection and testing,
generation of seroincidence data will inevitably have a built-in
delay. However, to be useful for policy makers, ‘‘real time’’
predictive models require more timely estimates of how incidence
is changing, particularly in the early stages of the pandemic. This
will require the use of clinical surveillance data derived from
individuals accessing health care which can be available daily if
required. While such data may accurately reflect the time course of
the pandemic, it will underestimate the true incidence of infection
and requires the use of a scaling factor for model parameterization
reflecting an estimate of the consultation rate per infection, as
described by Baguelin et al. [1]. Moreover, estimation of the
infection rate using clinical surveillance data is difficult until the
epidemic peaks when the depletion of susceptibles can then be
relatively accurately calculated providing there is an independent
measure of the basic reproductive ratio R0. The method presented
in this paper provides an improved tool to estimate incidence
earlier in an emerging epidemic, thus allowing earlier estimation of
the scaling factor that needs to be applied to the clinical
surveillance data used for model updating. As more serologic
data become available, revised estimates of the scaling factor can
then be produced using a Bayesian framework (the current
estimate is used as prior and the new samples provide a new
likelihood function).
Our estimated number of infections in the second wave were 20
to 40 fold higher than the number of clinical cases estimated by the
HPA, based on ILI consultations in individuals with confirmed
H1N1 (2009), scaled up by the estimated proportion of patients
with ILI who seek health care [6]. The difference between the
clinical case estimates and our infection estimates will reflect both
the proportion of infections that are asymptomatic and the real
proportion of patients with ILI seeking health care. The fold
difference between infections and the HPA clinical case estimates
was around 10 in the first wave [1,2]. Since the symptomatic/
asymptomatic ratio is unlikely to have changed between the first
and second waves, these fold differences are consistent with the
suggestion that there was a lower propensity to consult in the
second than the first wave [19].
In summary, our likelihood-based estimation method provides a
more accurate measure of incidence than achieved by comparing
prevalence in samples grouped by time period. It allows the
generation of a continuous curve that describes how incidence is
changing over the course of the pandemic and removes the
possibility of generating negative incidence estimates by sampling
error. It also obviates the need for pre-pandemic samples to
establish the antibody prevalence at baseline. The method has
potential for further development to incorporate and estimate the
effect of other variables influencing changes in antibody
prevalence, such as vaccination or waning immunity after
infection. It has general applicability to any sequential serologic
data set obtained over a period of changing incidence.
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